GO-OBSERVE

Europäische prospektive Beobachtungsstudie zum subjektiv (vom Patienten) beurteilten kontinuierlichen klinischen Ansprechen auf SIMPONI bei Erwachsenen mit moderater bis schwerer aktiver Colitis ulcerosa

Anprechpartner: Dr. A. Schirbel

EARNEST - Vedolizumab bei chronischer Pouchitis

A Randomized, Double-Blind, Placebo-Controlled Phase 4 Study to Evaluate the Efficacy and Safety of Entyvio (Vedolizumab IV) in the Treatment of Chronic Pouchitis

Anprechpartner: Dr. A. Fischer

GA29144 - Etrolizumab bei M. Crohn

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an Induction And Maintenance Treatment For Patients With Moderately to Severely Active Crohn's Disease

Anprechpartner: Dr. A. Fischer

GS-US-419-3895 - Filgotinib bei M. Crohn

Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Crohn's Disease

Anprechpartner: Dr. A. Fischer

STARDUST - Ustekinumab-Dosisstudie bei M. Crohn

Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab

Anprechpartner: Dr. A. Fischer

TRIDENT - JNJ-64304500 bei M. Crohn

A phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter protocol to evaluate the safety and efficacy of JNJ-64304500 in subjects with moderately to severely active Crohn's disease

Anprechpartner: Dr. A. Fischer

MUCUS - Mukosaheilung bei M. Crohn unter Ustekinumab

Induction and maintenance of mucosal healing in Crohn's disease with Ustekinumab in clinical practice

Ansprechpartner: Dr. A. Fischer

CARMEN - SHP647 bei M. Crohn 

Efficacy and Safety Study of SHP647 as maintenance Treatment in Participants with Moderate to Severe Crohn's Disease (CARMEN CD 307)

Ansprechpartner: Dr. A. Fischer

FIGARO - SHP647 bei Colitis ulcerosa

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants with Moderate to Severe Ulcerative Colitis (FIGARO UC 302

Ansprechpartner: Dr. A. Fischer

GALAXI - Guselkumab bei M. Crohn

A Study of the Efficacy and Safety of Guselkumab in Participants with moderately to severely active Crohn's Disease

Ansprechpartner: Dr. A. Fischer

LATTICE - BMS-986165  bei M. Crohn

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Crohn's Disease

Ansprechpartner: Dr. A. Fischer

YELLOWSTONE - Ozanimod  bei M. Crohn

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of oral ozanimod as induction therapy for Moderately to severely active Crohn's Disease

Ansprechpartner: Dr. A. Fischer